95 related articles for article (PubMed ID: 10762015)
1. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms.
Kirschbaum MH; Yarden Y
J Cell Biochem Suppl; 2000; 34():52-60. PubMed ID: 10762015
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic growth factor receptors: implications for signal transduction therapy.
Mosesson Y; Yarden Y
Semin Cancer Biol; 2004 Aug; 14(4):262-70. PubMed ID: 15219619
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
5. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
6. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction and oncogenesis by ErbB/HER receptors.
Marmor MD; Skaria KB; Yarden Y
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):903-13. PubMed ID: 14967450
[TBL] [Abstract][Full Text] [Related]
9. Role of HER2/neu in tumor progression and therapy.
Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
[TBL] [Abstract][Full Text] [Related]
10. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
12. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy.
Eccles SA; Modjtahedi H; Box G; Court W; Sandle J; Dean CJ
Invasion Metastasis; 1994-1995; 14(1-6):337-48. PubMed ID: 7657527
[TBL] [Abstract][Full Text] [Related]
13. Neuregulins and cancer.
Montero JC; Rodríguez-Barrueco R; Ocaña A; Díaz-Rodríguez E; Esparís-Ogando A; Pandiella A
Clin Cancer Res; 2008 Jun; 14(11):3237-41. PubMed ID: 18519747
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
15. Targeting epidermal growth factor receptor in head and neck cancer.
Ford AC; Grandis JR
Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
[TBL] [Abstract][Full Text] [Related]
16. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
17. Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers.
O'Rourke DM; Zhang X; Greene MI
Proc Assoc Am Physicians; 1997 May; 109(3):209-19. PubMed ID: 9154637
[TBL] [Abstract][Full Text] [Related]
18. Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.
Fink-Retter A; Gschwantler-Kaulich D; Hudelist G; Mueller R; Kubista E; Czerwenka K; Singer CF
Oncol Rep; 2007 Aug; 18(2):299-304. PubMed ID: 17611648
[TBL] [Abstract][Full Text] [Related]
19. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
20. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
Diehl KM; Grewal N; Ethier SP; Woods-Ignatoski KM
J Surg Res; 2007 Sep; 142(1):162-9. PubMed ID: 17612563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]